Compound Planning Inc. Raises Stake in GSK PLC Sponsored ADR $GSK

Key Points

• Compound Planning Inc. significantly increased its holdings in GSK PLC by 86.5% in Q1, owning 25,154 shares valued at $974,000 at the end of the reporting period.
• GSK reported a better-than-expected quarterly performance with earnings of $1.23 per share and revenue of $10.64 billion, surpassing analysts' expectations by a significant margin.
• The company disclosed a quarterly dividend of $0.4206 per share, with a total annualized dividend of $1.68, representing a yield of 4.2%.

Compound Planning Inc. grew its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 86.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 25,154 shares of the pharmaceutical company's stock after acquiring an additional 11,664 shares during the quarter. Compound Planning Inc.'s holdings in GSK were worth $974,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Voloridge Investment Management LLC lifted its holdings in shares of GSK by 1,360.4% during the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after purchasing an additional 2,016,795 shares during the period. Woodline Partners LP acquired a new stake in shares of GSK during the fourth quarter worth about $36,665,000. Miller Howard Investments Inc. NY lifted its holdings in shares of GSK by 138.4% during the first quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company's stock worth $63,797,000 after purchasing an additional 955,891 shares during the period. Schonfeld Strategic Advisors LLC lifted its holdings in shares of GSK by 68.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,237,034 shares of the pharmaceutical company's stock worth $75,656,000 after purchasing an additional 907,068 shares during the period. Finally, Kahn Brothers Group Inc. acquired a new stake in shares of GSK during the fourth quarter worth about $29,921,000. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Price Performance

Shares of GSK traded up $0.06 during trading hours on Friday, hitting $39.50. 1,805,078 shares of the stock were exchanged, compared to its average volume of 5,091,637. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.26. The company has a market cap of $80.44 billion, a price-to-earnings ratio of 18.28, a price-to-earnings-growth ratio of 1.73 and a beta of 0.51. The stock's 50-day moving average price is $38.37 and its two-hundred day moving average price is $38.20.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same period in the previous year, the business earned $0.43 earnings per share. The firm's revenue for the quarter was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Research analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a $0.4206 dividend. This represents a $1.68 annualized dividend and a yield of 4.3%. The ex-dividend date is Friday, August 15th. GSK's dividend payout ratio is presently 77.78%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on GSK shares. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Reduce" and an average target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.